Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma
Journal of Clinical Oncology · 2025-10 · 43 (28) · 3081-3089
DOI: 10.1200/jco-25-00610 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025-10. Verfasst von Yang Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, S…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Lymph Node Excision, Lymph Nodes. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Systematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non–small cell lung cancer. We aimed to investigate whether no mediastinal LND was noninferior to systematic LND in patients with ground glass opacity (GGO)–dominant invasive lung adenocarcinoma. METHODS We conducted a multicenter, open-label, phase III, noninferiority randomized controlled trial comparing systematic mediastinal LND versus no mediastinal LND in patients with GGO-dominant invasive lung adenocarcinoma, who were predicted to have no lymph node metastasis on the basis of criteria established in our previous trial. The primary end point was 3-year disease-free survival. An interim analysis was planned upon enrollment of 300 patients, with predefined termination criteria if no mediastinal lymph node metastasis is detected and life-threatening complications occur in the systematic LND arm. This trial is registered on ClinicalTrials.gov (ECTOP-1009, identifier: NCT04527419 ). RESULTS Interim analysis of 302 patients revealed no lymph node metastasis in either study arm. The no LND arm had significantly reduced surgery duration (mean, 74 minutes v 109 minutes; P < .001), blood loss (mean, 44 mL v 82 mL; P = .033), and postoperative hospital stay (mean, 3.9 days v 4.5 days; P = .002). Complications observed in the systematic LND arm included chylothorax in one patient (0.7%) and intraoperative massive bleeding because of superior vena cava injury in one patient (0.7%). No lymphadenectomy-related complications occurred in the no LND arm. CONCLUSION On the basis of interim findings and the principle of nonmaleficence, the trial should be terminated. Systematic mediastinal LND should no longer be recommended for patients with GGO-dominant lung adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
- Institute of Thoracic Oncology, Fudan University, Shanghai, People's Republic of China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
- Department of Thoracic Surgery, Jiangdu People's Hospital Affiliated to Medical College of Yangzhou University, Jiangsu, People's Republic of China.
- Department of Thoracic Surgery, Liaocheng Cancer Hospital, Shandong, People's Republic of China.
- Department of Thoracic Surgery, Liaocheng Second People's Hospital, Shandong, People's Republic of China.
ORCID-Profile: Hang Cao, Chaoqiang Deng, Ting Ye, Yihua Sun, Yueren Yan, Fangqiu Fu, Haiquan Chen
Zitieren
APA
Zhang, Y., Qian, B., Song, Q., Ma, J., Cao, H., Deng, C., Wang, S., Ye, T., Xiang, J., Zhang, Y., Sun, Y., Yan, Y., Zheng, S., Wu, H., Huang, Q., Hu, H., Li, Y., Fu, F., & Chen, H. (2025). Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma. Journal of Clinical Oncology, 43(28), 3081-3089. https://doi.org/10.1200/jco-25-00610
Vancouver
Zhang Y, Qian B, Song Q, Ma J, Cao H, Deng C, et al. Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma. Journal of Clinical Oncology. 2025;43(28):3081-3089. doi:10.1200/jco-25-00610
BibTeX
@article{Zhang2025,
author = {Zhang, Yang and Qian, Bin and Song, Qingping and Ma, Junjie and Cao, Hang and Deng, Chaoqiang and Wang, Shengping and Ye, Ting and Xiang, Jiaqing and Zhang, Yawei and Sun, Yihua and Yan, Yueren and Zheng, Shanbo and Wu, Haoxuan and Huang, Qingyuan and Hu, Hong and Li, Yuan and Fu, Fangqiu and Chen, Haiquan},
title = {Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {28},
pages = {3081--3089},
doi = {10.1200/jco-25-00610}
}
EUVIMED